- Home
- ALXO vs RDAC Comparison
ALXO vs RDAC Comparison
Compare ALXO & RDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- RDAC
- Stock Information
- Founded
- ALXO 2015
- RDAC 2024
- Country
- ALXO United States
- RDAC China
- Employees
- ALXO N/A
- RDAC N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- RDAC
- Sector
- ALXO Health Care
- RDAC
- Exchange
- ALXO Nasdaq
- RDAC NYSE
- Market Cap
- ALXO 76.5M
- RDAC 75.2M
- IPO Year
- ALXO 2020
- RDAC 2024
- Fundamental
- Price
- ALXO $1.12
- RDAC $10.10
- Analyst Decision
- ALXO Buy
- RDAC
- Analyst Count
- ALXO 6
- RDAC 0
- Target Price
- ALXO $6.64
- RDAC N/A
- AVG Volume (30 Days)
- ALXO 769.2K
- RDAC 457.0
- Earning Date
- ALXO 03-06-2025
- RDAC 01-01-0001
- Dividend Yield
- ALXO N/A
- RDAC N/A
- EPS Growth
- ALXO N/A
- RDAC N/A
- EPS
- ALXO N/A
- RDAC N/A
- Revenue
- ALXO N/A
- RDAC N/A
- Revenue This Year
- ALXO N/A
- RDAC N/A
- Revenue Next Year
- ALXO N/A
- RDAC N/A
- P/E Ratio
- ALXO N/A
- RDAC N/A
- Revenue Growth
- ALXO N/A
- RDAC N/A
- 52 Week Low
- ALXO $0.96
- RDAC $9.98
- 52 Week High
- ALXO $17.83
- RDAC $10.41
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- RDAC N/A
- Support Level
- ALXO $1.00
- RDAC N/A
- Resistance Level
- ALXO $1.22
- RDAC N/A
- Average True Range (ATR)
- ALXO 0.09
- RDAC 0.00
- MACD
- ALXO 0.00
- RDAC 0.00
- Stochastic Oscillator
- ALXO 35.12
- RDAC 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About RDAC RISING DRAGON ACQUISITION CORP
Rising Dragon Acquisition Corp is a blank check company.